| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
389,580,000 |
| Market
Cap: |
50.01(B) |
| Last
Volume: |
1,778,975 |
Avg
Vol: |
1,913,734 |
| 52
Week Range: |
$75.49 - $140.45 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 487 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
214,480 |
283,298 |
303,316 |
571,262 |
| Total Sell Value |
$28,881,982 |
$37,155,070 |
$39,545,240 |
$69,827,197 |
| Total People Sold |
7 |
12 |
14 |
16 |
| Total Sell Transactions |
14 |
29 |
47 |
80 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sayer Kevin R |
President CEO and Chairman of |
• • – |
2022-11-03 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
381,532 |
|
- |
|
| Selvaraj Shelly Ramasamy |
SVP Chief Information Officer |
• – – |
2022-09-08 |
4 |
A |
$0.00 |
$4 |
D/D |
4,051 |
49,942 |
|
- |
|
| Dolan Matthew Vincent |
SVP Corporate Strategy-Develop |
• – – |
2022-09-01 |
4 |
AS |
$81.63 |
$408 |
D/D |
(5) |
26,536 |
|
31% |
|
| Pacelli Steven Robert |
EVP Managing Director Dexcom V |
• – – |
2022-08-23 |
4 |
AS |
$84.21 |
$84,210 |
D/D |
(1,000) |
137,700 |
|
37% |
|
| Dahut Karen M |
Director |
– • – |
2022-08-11 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,548 |
6,768 |
|
- |
|
| Dahut Karen M |
Director |
– • – |
2022-08-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,548 |
5,492 |
|
- |
|
| Pacelli Steven Robert |
EVP Managing Director Dexcom V |
• – – |
2022-07-25 |
4 |
AS |
$83.07 |
$83,070 |
D/D |
(1,000) |
138,700 |
|
41% |
|
| Pacelli Steven Robert |
EVP Managing Director Dexcom V |
• – – |
2022-06-23 |
4 |
AS |
$72.55 |
$72,550 |
D/D |
(1,000) |
139,700 |
|
54% |
|
| Sylvain Jereme M |
EVP Chief Financial Officer |
• – – |
2022-06-06 |
4 |
AS |
$301.57 |
$180,942 |
D/D |
(600) |
17,408 |
|
-67% |
|
| Pacelli Steven Robert |
EVP Managing Director Dexcom V |
• – – |
2022-05-24 |
4 |
AS |
$296.33 |
$74,083 |
D/D |
(250) |
35,175 |
|
-68% |
|
| Foletta Mark G |
Director |
– • – |
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
1,122 |
1,122 |
|
- |
|
| Skyler Jay S |
Director |
– • – |
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
969 |
969 |
|
- |
|
| Dahut Karen M |
Director |
– • – |
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
987 |
1,760 |
|
- |
|
| Topol Eric |
Director |
– • – |
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
988 |
988 |
|
- |
|
| Augustinos Nicholas |
Director |
– • – |
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
994 |
994 |
|
- |
|
| Altman Steven R |
Director |
– • – |
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
979 |
979 |
|
- |
|
| Malady Kyle |
Director |
– • – |
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
979 |
3,161 |
|
- |
|
| Kahn Barbara |
Director |
– • – |
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
994 |
994 |
|
- |
|
| Collins Richard Alexander |
Director |
– • – |
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
987 |
987 |
|
- |
|
| Heller Bridgette P |
Director |
– • – |
2022-05-20 |
4 |
A |
$0.00 |
$1 |
D/D |
988 |
5,355 |
|
- |
|
| Foletta Mark G |
Director |
– • – |
2022-05-19 |
4 |
A |
$0.00 |
$0 |
I/I |
1,054 |
13,651 |
|
- |
|
| Foletta Mark G |
Director |
– • – |
2022-05-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,054) |
0 |
|
- |
|
| Skyler Jay S |
Director |
– • – |
2022-05-19 |
4 |
A |
$0.00 |
$0 |
I/I |
900 |
14,868 |
|
- |
|
| Skyler Jay S |
Director |
– • – |
2022-05-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(900) |
0 |
|
- |
|
| Dahut Karen M |
Director |
– • – |
2022-05-19 |
4 |
A |
$0.00 |
$0 |
I/I |
918 |
1,305 |
|
- |
|
2278 Records found
|
|
Page 7 of 92 |
|
|
1.72 (1.36%) 
